Diabetic Retinopathy
Conditions
Brief summary
The main objective of this study is to evaluate the efficacy at 6 months of omega 3 supplementation on macular capillary density measured in optical coherence tomography angiography in patients with minimal or moderate non proliferative diabetic retinopathy.
Detailed description
Diabetic retinopathy (DR) is a leading cause of vision loss worldwide and is a major public health problem. In Western countries, the prevalence of DR is estimated to be 35% in diabetic patients, while diabetic macular edema (DME) affects 5% of them. Currently, apart from the balance of diabetes and other cardiovascular risk factors, no specific treatment is given for the minimal and moderate non-proliferative forms. * DHA concentration in the retina can be modified according to the patient's diet. * Minimal diabetic retinopathy does not currently benefit from specific treatment outside of diabetic control. * Omega 3 are already known for their beneficial effects on the retina, brain and cardiovascular system but their effectiveness has not been tested on diabetic retinopathy. * It is therefore a question of evaluating whether an omega 3 supplementation, at a dosage of 1000mg per day, can treat a minimal or moderate stage of diabetic retinopathy. A study by Salavila et al. has shown that the intake of LCω3PUFA, via a Mediterranean diet, improved the stage of DR in diabetic patients.
Interventions
DIETARY_SUPPLEMENTNutrof
DHA docosahexaenoic acid Omega 3s may be of interest in cases of retinopathies.
DIETARY_SUPPLEMENTMeralut
vitamin A, natural flavonoids, lutein and zeaxanthin
Sponsors
Laboratoires Thea
Centre Hospitalier Intercommunal Creteil
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ≥18 years * For women of childbearing age, an effective method of contraception is introduced and monitored throughout their participation in the study. * Diabetic microangiopathy: minimal to moderate nonproliferative diabetic retinopathy according to the ETDRS (EarlyTreatment of DiabeticRetinopathyStudy) classification. * AV \> 6/10 * One eye included. If both are affected, the eye with the poorer perfusion should be included. * Affiliated to a social security scheme
Exclusion criteria
* \< 18 years old. * Pregnant or breastfeeding woman * Other retinal pathologies that may interfere with the results (Patients previously treated with anti-VEGF, aflibercept or intra-vitreal corticosteroids, history of glaucoma, vitrectomy, retinal laser, epiretinal membrane), choroidal neo-vascularization, uveitis, retinal vascular occlusion, significant macular edema, macular thickness \> 280 µm, Eyes with spherical equivalent greater than 8 Diopters, OCTA images not interpretable with many artifacts.) * Hypersensitivity to any of the components of Nutrof or Meralut * Taking the antivitamin k * Known deficit in G6PD- * History of renal lithiasis * Kidney failure * Immunosuppression * Chronic Ethylism * History of hepatopathy * Intracranial tumor, intracranial hypertension * Refusal to participate * Patient participating in an intervention study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| density of the deep capillary plexus in optical coherence tomography angiography (OCTA) | six months | Macular vascularization consists of three interconnected capillary plexuses: the superficial capillary plexus (SCp) located at the level of the optic fibres and the intermediate (ICP) and deep (DCP) capillary plexuses located respectively at the level of the inner and outer part of the inner nuclear layer.16 OCTA is a non-invasive imaging method of retinal vasculature that allows a qualitative but mainly quantitative analysis of the capillary plexuses. A last parameter that could not be evaluated precisely with the old fluorescein and OCT angiography techniques. OCTA is performed without injection of intravenous contrast agent and has no side effects. Several studies have shown that PCP is the plexus most affected by non-perfusion areas in diabetic retinopathy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| area (mm²) of the central avascular zone in OCTA | six months | area (mm² |
| Visual acuity measurement ETDRS | six months | Visual acuity |
| Stage of diabetic retinopathy: minimal, moderate or severe | six months | Each stage of retinopathy may be associated with some degree of diabetic macular edema; macular edema is classified as minimal, moderate or severe, depending on its location relative to the centre of the macula. It is considered severe when it reaches the centre of the macula. Non-proliferative diabetic retinopathy (NPDR, no neo-vessels) Minimal non-proliferative DR (some microaneurysms or punctiform hemorrhages). * Moderate nonproliferative DR (by exclusion if neither minimal nor severe DRNP) * Severe nonproliferative DR (or preproliferative DR): 4, 2, 1 rule (retinal hemorrhages in 4 quadrants and/or venous dilatations in 2 quadrants and/or AMIR in 1 quadrant) |
| central retinal thickness (µm) in the 2 groups at 6 months | six months | central retinal thickness |
| capillary plexus density in OCTA | six months | capillary plexus density |
| triglycerid level | six months | triglycerid level |
| glycated haemoglobin (percent) | six months | In diabetes, the higher the blood glucose level, the more glucose attaches to hemoglobin and the higher the level of glycated hemoglobin. It therefore indicates whether the blood glucose level was, on average, higher or lower during the 2 months prior to the test. Glycated haemoglobin is measured every 2-4 months. A small amount of blood is drawn from a vein or from the fingertip (micro-method). Glycated haemoglobin (HbA1c) is a fundamental criterion for blood sugar control. It is essential for assessing the risk of complications. 9% Very high 7% Recommended 5% Normal |
| Diet questionnaire | six months | questionnaire |
| cholesterol level: Low-density lipoprotein, High-density lipoprotein and total cholesterol | six months | cholesterol leve |
Countries
France
Outcome results
None listed